Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab plus daratumumab versus daratumumab-based triplets in relapsed or refractory multiple myeloma
NL-OMON58845Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of teclistamab, sponsored by Janssen Pharmaceutical. Started Jan 2022; status: active, not recruiting.
02
Drugs
teclistamab
Beyond the preview
Go deeper on NL-OMON58845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58845.